Expert opinion on drug metabolism & toxicology最新文献_第5页

Sex-gender differences in pharmacokinetics. 药代动力学的性别差异。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-13 DOI: 10.1080/17425255.2025.2479115

Ilaria Campesi, Flavia Franconi

引用次数: 0

The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury. 细胞色素 P450 还原酶（CPR）在高氧肺损伤中的核心作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-02-25 DOI: 10.1080/17425255.2025.2470808

Deven Narke, Bhagavatula Moorthy

{"title":"The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury.","authors":"Deven Narke, Bhagavatula Moorthy","doi":"10.1080/17425255.2025.2470808","DOIUrl":"10.1080/17425255.2025.2470808","url":null,"abstract":"Introduction: Hyperoxic lung injury results from excessive supplemental oxygen therapy in conditions such as bronchopulmonary dysplasia (BPD) in preterm infants and acute respiratory distress syndrome (ARDS) in adults. This review explores the role of cytochrome P450 reductase (CPR) in hyperoxic lung injury.Areas covered: Hyperoxia induces the production of reactive oxygen species in excessive amounts, overwhelming the body's antioxidant defenses and exacerbating lung injury in ARDS/BPD. This review examines the differential roles of CPR-dependent enzymes in the context of hyperoxic lung injury. Additionally, we highlight the potential of targeting CPR to study mechanisms of lung injury and leverage gene-editing technologies to deepen our understanding of CPR-mediated pathways. This review consolidates existing knowledge on CPR-dependent processes and their roles in hyperoxic lung injury, based on a literature search conducted in the PubMed database for studies published between 1988 and 2024.Expert opinion: This review emphasizes the need for a deeper understanding of disease mechanisms, particularly CPR-mediated pathways. As a regulatory hub for ROS modulation and enzyme activity, CPR represents a promising target, offering a unified strategy to mitigate hyperoxic lung injury and improve outcomes in BPD/ARDS.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"589-598"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies. 同时使用口服抗凝血剂和降糖药的安全性：观察性研究的系统回顾。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1080/17425255.2025.2474128

Paraskevi Tassopoulou, Wanqi Wang, Fabian Maximilian Meinert, Thomas G Riemer, Antonios Douros

{"title":"Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies.","authors":"Paraskevi Tassopoulou, Wanqi Wang, Fabian Maximilian Meinert, Thomas G Riemer, Antonios Douros","doi":"10.1080/17425255.2025.2474128","DOIUrl":"10.1080/17425255.2025.2474128","url":null,"abstract":"Introduction: We systematically reviewed observational studies assessing the safety of concomitant use of oral anticoagulants (OACs) and antidiabetic drugs (ADs).Methods: We systematically searched MEDLINE/PubMed and EMBASE up to 10/2024 for cohort, case-control, and case-only studies on concomitant use of OACs and ADs and the risk of adverse outcomes (hypoglycemia, bleeding). Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.Results: We identified five cohort studies and two self-controlled case-series (n = 1,370,036). Concomitant use of sulfonylureas and warfarin was mostly associated with increased risks of hypoglycemia versus sulfonylurea use alone (five studies); results were heterogeneous when comparing concomitant use of sulfonylureas and warfarin versus concomitant use of sulfonylureas and DOACs (two studies) and concomitant use of non-sulfonylurea ADs and warfarin versus non-sulfonylurea AD use alone (two studies). Concomitant use of warfarin and sulfonylureas was not associated with the risk of bleeding versus warfarin use alone (one study). Via ROBINS-I, four studies were at moderate, one at serious, and two at critical risk of bias.Conclusions: Given inconsistent findings and a non-negligible risk of bias, observational studies do not suggest major clinical hazards due to concomitant use of OACs and ADs. (PROSPERO registration: CRD42024505475).","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"617-624"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The quest to define cancer-specific systems parameters for personalized dosing in oncology. 为肿瘤学个体化给药确定癌症特异性系统参数的探索。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-24 DOI: 10.1080/17425255.2025.2476560

Areti-Maria Vasilogianni, Brahim Achour, Zubida M Al-Majdoub, Sheila Annie Peters, Jill Barber, Amin Rostami-Hodjegan

{"title":"The quest to define cancer-specific systems parameters for personalized dosing in oncology.","authors":"Areti-Maria Vasilogianni, Brahim Achour, Zubida M Al-Majdoub, Sheila Annie Peters, Jill Barber, Amin Rostami-Hodjegan","doi":"10.1080/17425255.2025.2476560","DOIUrl":"10.1080/17425255.2025.2476560","url":null,"abstract":"Introduction: Clinical trials in oncology initially recruit heterogeneous populations, without catering for all types of variability. The target cohort is often not representative, leading to variability in pharmacokinetics (PK). To address enrollment challenges in clinical trials, physiologically based pharmacokinetic models (PBPK) models can be used as a guide in the absence of large clinical studies. These models require patient-specific systems data relevant to the handling of drugs in the body for each type of cancer, which are scarce.Areas covered: This review explores system parameters affecting PK in cancer and highlights important gaps in data. Changes in drug-metabolizing enzymes (DMEs) and transporters have not been fully investigated in cancer. Their impaired expression can significantly affect capacity for drug elimination. Finally, the use of PBPK modeling for precision dosing in oncology is highlighted. Google Scholar and PubMed were mainly used for literature search, without date restriction.Expert opinion: Model-informed precision dosing is useful for dosing in sub-groups of cancer patients, which might not have been included in clinical trials. Systems parameters are not fully characterized in cancer cohorts, which are required in PBPK models. Generation of such data and application of cancer models in clinical practice should be encouraged.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"599-615"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hormones, microbes, and PrEP drugs in the female genital tract. 女性生殖道中的激素、微生物和PrEP药物。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-12 DOI: 10.1080/17425255.2025.2476792

Melanie R Nicol, Christopher M Olsem

引用次数: 0

The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis. 月经周期对抗癫痫药物和锂的药代动力学的影响：一项系统综述和荟萃分析。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-04-01 Epub Date: 2025-02-24 DOI: 10.1080/17425255.2025.2468197

Maximilian Gillessen, Chiara Theresa Schmidt, Kristina M Deligiannidis, Sarah Kittel-Schneider, Erich Seifritz, Torbjörn Tomson, Olav Spigset, Michael Paulzen, Georgios Schoretsanitis

{"title":"The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis.","authors":"Maximilian Gillessen, Chiara Theresa Schmidt, Kristina M Deligiannidis, Sarah Kittel-Schneider, Erich Seifritz, Torbjörn Tomson, Olav Spigset, Michael Paulzen, Georgios Schoretsanitis","doi":"10.1080/17425255.2025.2468197","DOIUrl":"10.1080/17425255.2025.2468197","url":null,"abstract":"Introduction: Our aim was to quantify the impact of menstrual cycle phases on the pharmacokinetics of antiseizure medications (ASM) and lithium.Methods: A systematic literature search was conducted in PubMed/EMBASE in March 2024 for studies comparing levels of ASM and/or lithium in the early follicular and luteal phase. Concentration ratios between the follicular and the luteal phase were calculated. We performed a random-effects meta-analysis calculating between-timepoint differences in plasma concentration mean differences (MDs) and 95% confidence intervals (95% CIs). Subgroup analyses included cohorts stratified by the occurrence of catamenial exacerbation. Study quality was assessed using the ClinPK guidelines.Results: Fifteen studies investigating six ASM and lithium in 224 subjects were included. The highest concentration ratio was reported for carbamazepine (1.27, range 0.89-2.13) with an MD of 0.57 μg/mL, 95% CI: 0.41 to 0.72. Phenytoin concentration fluctuations were larger in subjects with (MD -3.51 μg/mL, 95% CI = -4.97 to -2.06) vs. without catamenial exacerbations (MD -1.18 μg/mL, 95% CI = -2.51 to 0.14, p = 0.02). Study quality was acceptable with an average rating score of 13.1.Conclusions: Data do not suggest major changes in ASM pharmacokinetics across the menstrual cycle. Participants with vs. without catamenial exacerbation had larger phenytoin concentration decreases in the early follicular compared to the luteal phase.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024527321.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"481-490"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human liver cell-based assays for the prediction of hepatic bile acid efflux transporter inhibition by drugs. 以人肝细胞为基础预测药物对肝胆汁酸外排转运体抑制作用的试验。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-04-01 Epub Date: 2025-01-20 DOI: 10.1080/17425255.2025.2453486

Olivier Fardel, Amélie Moreau, Elodie Jouan, Claire Denizot, Marc Le Vée, Yannick Parmentier

{"title":"Human liver cell-based assays for the prediction of hepatic bile acid efflux transporter inhibition by drugs.","authors":"Olivier Fardel, Amélie Moreau, Elodie Jouan, Claire Denizot, Marc Le Vée, Yannick Parmentier","doi":"10.1080/17425255.2025.2453486","DOIUrl":"10.1080/17425255.2025.2453486","url":null,"abstract":"Introduction: Drug-mediated inhibition of bile salt efflux transporters may cause liver injury. In vitro prediction of drug effects toward canalicular and/or sinusoidal efflux of bile salts from human hepatocytes is therefore a major issue, which can be addressed using liver cell-based assays.Area covered: This review, based on a thorough literature search in the scientific databases PubMed and Web of Science, provides key information about hepatic transporters implicated in bile salt efflux, the human liver cell models available for investigating functional inhibition of bile salt efflux, the different methodologies used for this purpose, and the modes of expression of the results. Applications of the assays to drugs are summarized, with special emphasis to the performance values of some assays for predicting hepatotoxicity/cholestatic effects of drugs.Expert opinion: Human liver cell-based assays for evaluating drug-mediated inhibition of bile acid efflux transporters face various limitations, such as the lack of method standardization and validation, the present poor adaptability to high throughput approaches, and some pitfalls with respect to interpretation of bile acid biliary excretion indexes. Hepatotoxicity of drugs is additionally likely multifactorial, highlighting that inhibition of hepatic bile salt efflux by drugs provides important, but not full, information about potential drug hepatotoxicity.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"463-480"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive review of the efficacy and safety of ertugliflozin. 厄图格列净疗效和安全性的综合评价。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI: 10.1080/17425255.2025.2457393

Bo Xu, Yilin Liu, Tianqiao Zhang, Zunbo He, Jiecan Zhou

{"title":"A comprehensive review of the efficacy and safety of ertugliflozin.","authors":"Bo Xu, Yilin Liu, Tianqiao Zhang, Zunbo He, Jiecan Zhou","doi":"10.1080/17425255.2025.2457393","DOIUrl":"10.1080/17425255.2025.2457393","url":null,"abstract":"Introduction: Ertugliflozin is the fourth sodium-glucose co-transporter (SGLT2) inhibitor approved by the US FDA in 2017 for the treatment of type 2 diabetes mellitus.Areas covered: The main purpose of this review is to evaluate the clinical efficacy and safety of ertugliflozin. We conducted a search of relevant literature on ertugliflozin in the PubMed and Web of Science databases up to 22 October 2024.Expert opinion: Ertugliflozin reduces the incidence of composite renal endpoints, maintain eGFR, and decreases urine albumin to creatinine ratio. Cardiovascular effects of ertugliflozin are primarily demonstrated in the VERTIS CV trial. However, the cardiovascular benefits of ertugliflozin are inferior to those of empagliflozin or canagliflozin. Ertugliflozin had non-significant impact on major adverse cardiovascular events, cardiovascular death, or hospitalization for heart failure (HHF); ertugliflozin did reduce the risk of HHF, including in elderly population. Notably, ertugliflozin did not significantly reduce NT-proBNP levels in heart failure patients, while it decreased the incidence of persistent ventricular tachycardia or ventricular fibrillation events. Ertugliflozin may be beneficial for ocular diseases or neurodegenerative diseases. Adverse events associated with ertugliflozin are similar to those of previously approved SGLT2 inhibitors, although it is associated with a higher overall risk of cancer, especially renal cancer.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"373-382"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug interactions in people with HIV treated with antivirals for other viral illnesses. 用抗病毒药物治疗其他病毒性疾病的HIV患者的药物相互作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI: 10.1080/17425255.2025.2455401

Adaora Okoli, Onyema Ogbuagu

{"title":"Drug interactions in people with HIV treated with antivirals for other viral illnesses.","authors":"Adaora Okoli, Onyema Ogbuagu","doi":"10.1080/17425255.2025.2455401","DOIUrl":"10.1080/17425255.2025.2455401","url":null,"abstract":"Introduction: Background: People with HIV (PWH) have benefited tremendously from effective antiretroviral(ARV) treatments. However, PWH are at increased risk for other viral infections transmitted in the same way as HIV (such as hepatitis C and MPox) or that are opportunistic (e.g. cytomegalovirus). These coinfections contribute significantly to morbidity and mortality among PWH and require effective treatments to optimize patient outcomes. However, their management is complicated by drug-drug interactions (DDIs) with ARVs.Areas covered: Metabolism pathways and DDIs between approved ARVs and selected antiviral agents used for the treatment of common and clinically relevant viral coinfections are discussed. Literature review included search of published papers, conference abstracts (IAS, CROI, IDWeek, EACS, Glasgow) as well as unpublished data from approved drug prescribing information and regulatory submissions sourced from PubMed, Google, and Google Scholar available between June 30 1981 through June 1, 2024.Expert opinion: Management of drug interactions is essential for maintaining efficacy and safety of ARV and other co-administered antiviral therapies. Longer acting agents are now available for treatment of HIV and this lengthens the period during which drug interactions may occur. Emerging novel nanoparticle-carrier targeted hepatitis C and HIV treatments may mitigate, if not eliminate, their propensity for drug-drug interactions.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"383-397"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of altered hepatic drug disposition during pregnancy: small molecules. 妊娠期间肝脏药物处置改变的机制：小分子。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-04-01 Epub Date: 2025-02-26 DOI: 10.1080/17425255.2025.2470792

Muluneh M Fashe, Jacqueline B Tiley, Craig R Lee

{"title":"Mechanisms of altered hepatic drug disposition during pregnancy: small molecules.","authors":"Muluneh M Fashe, Jacqueline B Tiley, Craig R Lee","doi":"10.1080/17425255.2025.2470792","DOIUrl":"10.1080/17425255.2025.2470792","url":null,"abstract":"Introduction: Pregnancy alters the systemic exposure and clearance of many hepatically cleared drugs that are commonly used by obstetric patients. Understanding the molecular mechanisms underlying the changes in factors that affect hepatic drug clearance (blood flow, protein binding, and intrinsic clearance) is essential to more precisely predict systemic drug exposure and dose requirements in obstetric patients.Areas covered: This review (1) summarizes the anatomic, physiologic, and biochemical changes in maternal hepatic, cardiovascular, endocrine, and renal systems relevant to hepatic drug clearance and (2) reviews the molecular mechanisms underlying the altered hepatic metabolism and intrinsic clearance of drugs during pregnancy via a comprehensive PubMed search. It also identifies knowledge gaps in the molecular mechanisms and factors that modulate hepatic drug clearance during pregnancy.Expert opinion: Pharmacokinetic studies have shown that pregnancy alters systemic exposure, protein binding, and clearance of many drugs during gestation in part due to pregnancy-associated decreases in plasma albumin, increases in organ blood flow, and changes in the activity of drug-metabolizing enzymes (DMEs) and transporters. The changes in the activity of certain DMEs and transporters during pregnancy are likely driven by hormonal-changes that inhibit their activity or alter the expression of these proteins through activation of transcription factors.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"445-462"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0